» Articles » PMID: 27482394

Recruitment and Ethical Considerations in HIV Cure Trials Requiring Treatment Interruption

Overview
Journal J Virus Erad
Date 2016 Aug 3
PMID 27482394
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Relative to antiretroviral treatment (ART), early HIV cure-related trials (HCRTs) carry limited therapeutic benefits and unknown risks. In HCRTs requiring treatment interruption (TI) the health risks and burdens may create a barrier to study enrolment and increase the possibility for unintentional ethical violations in recruitment.

Methods: An online survey was administered to over 2,000 HIV-positive ART users in the US. Using multivariable ordinal regression we assessed effects of research participation attitudes, health and demographic traits on willingness to participate in treatment interruption studies (WtP-TI).

Results: WtP-TI was greatest among those who were highly motivated to participate in research studies for the benefit of science, society and, to a lesser extent, personal benefit. Personal benefit was less of an influence on WtP-TI among persons with higher viral loads or a history of multiple ART regimens. WtP-TI was greater among respondents who were more likely to consider personal health in making decisions about trial participation. WtP-TI had no association with perceptions of the importance of compensation to research participation. After accounting for attitudes, health status and demographic traits were generally not significantly related to WtP-TI. Notable exceptions included viral suppression status and race/ethnicity.

Conclusion: Recruitment strategies in TI studies can benefit from a focus on the long-term scientific and social benefits of study participation. Strategies targeted to particular demographic groups may have little impact on accrual, and in some cases will need to be accompanied by strategies to improve the quality of researcher-community relationships. Findings also suggest that informing communities about the health impacts of trial participation may positively impact participation decisions. However, more research is needed to interpret the impact of health messaging on recruitment and therapeutic expectations. Future work should explore the implications of altruism-based expectations on the strategic and ethical appropriateness of TI study recruitment efforts.

Citing Articles

Relatively high interest but limited active engagement in HIV cure research: Awareness, interest, and information-seeking among affected communities in the Netherlands.

Noorman M, de Wit J, Marcos T, Stutterheim S, Albers T, Jonas K J Virus Erad. 2025; 10(4):100570.

PMID: 39760121 PMC: 11697764. DOI: 10.1016/j.jve.2024.100570.


Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.

Dube K, Ndukwe S, Korolkova A, Dee L, Sugarman J, Sauceda J HIV Res Clin Pract. 2024; 25(1):2312318.

PMID: 38348830 PMC: 10951555.


Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.

Bilger A, Plenn E, Barg F, Rendle K, Carter W, Lamour-Harrington A HIV Res Clin Pract. 2023; 24(1):2267825.

PMID: 37837376 PMC: 10634456.


The Importance of Social Engagement in the Development of an HIV Cure: A Systematic Review of Stakeholder Perspectives.

Noorman M, de Wit J, Marcos T, Stutterheim S, Jonas K, den Daas C AIDS Behav. 2023; 27(11):3789-3812.

PMID: 37329470 PMC: 10589186. DOI: 10.1007/s10461-023-04095-z.


Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings.

Saberi P, Campbell C, Sauceda J, Ndukwe S, Dube K AIDS Res Hum Retroviruses. 2022; 38(8):649-659.

PMID: 35579937 PMC: 9464049. DOI: 10.1089/AID.2021.0192.


References
1.
Mills E, Wilson K, Rachlis B, Griffith L, Wu P, Guyatt G . Barriers to participation in HIV drug trials: a systematic review. Lancet Infect Dis. 2005; 6(1):32-8. DOI: 10.1016/S1473-3099(05)70324-8. View

2.
Chun T, Fauci A . HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012; 26(10):1261-8. DOI: 10.1097/QAD.0b013e328353f3f1. View

3.
El-Sadr W, Affrunti M, Gamble T, Zerbe A . Antiretroviral therapy: a promising HIV prevention strategy?. J Acquir Immune Defic Syndr. 2011; 55 Suppl 2:S116-21. PMC: 3074403. DOI: 10.1097/QAI.0b013e3181fbca6e. View

4.
Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

5.
Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View